-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Cognition To Present ZUNVEYL Clinical Data At 2025 AAIC

Benzinga·04/28/2025 12:36:47
Listen to the news

Alpha Cognition Inc. (NASDAQ:ACOG) (the "Company" or "Alpha Cognition") today announced three upcoming presentations at the 2025 Alzheimer's Association International Conference (the "AAIC"), taking place July 27–31, 2025 in Toronto, Canada.

The presentations will highlight clinical studies supporting ZUNVEYL (benzgalantamine), the Company's lead product and a novel galantamine prodrug approved by the FDA in July 2024 and commercially launched in March 2025. The studies demonstrated bioequivalence to galantamine IR and ER and were integral to the NDA submission and approval.